Source Plasma Safety

Size: px
Start display at page:

Download "Source Plasma Safety"

Transcription

1 Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology

2 Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe High Quality Plasma Products Slide 2

3 Relative Risk Plasma Quality Steps Donor selection Testing donations NAT testing Inventory Hold (where applicable) Virus inactivation / removal steps Finished product From Donor to Patient Therapy Slide 3

4 Plasma Quality Steps Important Plasma Quality Steps Donor Screening Medical history and physical examination (protects donor health and reduces recipient risk) Laboratory Testing Qualified Donors (Source Plasma) 60 Day Inventory Hold (Source Plasma) Residual Risk Assessments Epidemiological [viral marker] standards Slide 4

5 Donor Selection National Donor Deferral Registry (U.S. Source Plasma) Reactive donors entered in national database for HIV, HBV, HCV Prospective donors must be checked in database before allowed to donate Community- Based Donor Standard No donors without permanent address. Donors must reside within defined recruitment area Valild photo ID Donor Education Standard Donors must be educated regarding HIV/AIDS Assessment of comprehension for new donors Slide 5

6 International Quality Plasma Program Donor Selection Standards Lowered Risk Viral Marker Standard Center s viral marker rates compared to industry average Centers repeatedly exceeding Alert Limits subject to lose IQPP certification Qualified Donor Standard New donors must pass 2 medical screenings and testing Reactivated donors (Qualified with > 6 month lapse) must requalify Slide 6

7 Quality Standards of Excellence, Assurance & Leadership QSEAL Standards Lowered Risk Inventory Hold Standard Plasma held in inventory for at least 60 days after donation Allows for interdetection and destruction of plasma based on post-donation disqualifiers NAT Testing Standard Requires NAT for HIV, HBV and HCV at minipool and at First Homogeneous Pool level Requires in-process testing for HAV and Parvovirus B19 Slide 7

8 Viral Marker Standard A statistically reliable system to ensure collection from quality Source Plasma collection centers, based on viral marker rates. In place for over a decade Serves as a guide for quality improvement Marker specific for HIV, HCV, and HBV Academic peer-reviewed Approach endorsed by FDA Slide 8

9 Viral Marker Alert Limits Alert Levels allow for identification of centers with higher than expected viral positivity rates. Allows for continuous epidemiological evaluation at individual plasma collection centers together with an annual update of the assessment. Reference rates based on overall industry averages for donors contributing to the pool, measured in a defined time period with the most appropriate testing technology. Slide 9

10 Donations (10 6 ) 13,233,773 13,824,545 12,644,462 10,317,674 10,368,480 12,442,214 15,326,821 18,817,869 22,028,860 19,807,473 23,573,488 26,214,019 29,391,097 32,550,293 35,464,612 38,296, Slide 10

11 # Centers Number U.S. Centers 600 Number of US Source Plasma Centers Slide 11

12 Qualified Donor Positivity Rates Slide 12

13 Residual Risk Estimates of a potentially infectious unit being released for fractionation or transfusion Slide 13

14 Residual Risk Residual Risk of Viral Agent Entering the Manufacturing Pool The presence of certain viruses in asymptomatic donors who are negative on the screening tests (window period donations) constitutes the major risk of viruses entering the fractionation process. The Residual Risk is the estimated probability of a potentially infectious plasma unit entering the manufacturing pool. Accounts for industry inventory hold. Used to assess the impact of industry safety initiatives. Can be used to estimate pool viral load. The viruses of concern are: HCV, HIV, and HBV. Slide 14

15 Residual Risk / 10 6 Donations HIV and HCV Residual Risk HIV HCV Slide 15

16 Residual Risk / 106 Donations HBV Residual Risk Slide 16

17 Odds of Dying: What we Should Fear Odds versus Risk Odds per 1,000,000 Cancer (lifetime) 142,857 Hospital Infection (lifetime) 26,316 Complications of Medical Surgical Care (lifetime) 762 Exposure to Forces of Nature (lifetime) 574 Drowning in a Bathtub (lifetime) 90 Killed by a dog (lifetime) 9 Asteroid Impact (Lifetime) 5 Struck by Lighting (year) 2.5 Versus Risk of: A Potentially Infectious Source Plasma Unit Making it to the Manufacturing Pool 1-8 Slide 17

18 Key Points to Remember Residual risk for Source Plasma not the same as RR for whole blood. WB is risk of transmission by transfusion. Source Plasma is risk of a POTENTIALLY contaminated unit entering manufacturing pool. Potentially contaminated units have detection levels below that of the NAT test. All manufactured Source Plasma derived products have virus removed or inactivated. Residual risk of transmission is then reduced to zero. Slide 18

19 Effectiveness of Inventory Hold in Reducing Residual Risk (per 10 6 ) Inventory Hold 2014 Residual Risk 2015 Residual Risk Hold 0-Day Hold 60-Day No Hold /60-Day % Reduction Hold 0-Day Hold 60- Day No Hold /60 days % Reduction HIV HCV HBV Slide 19

20 Residual Risk Percent Percent of Residual Risk (Incidence Donor / Total) No Hold 60-day Hold HIV HCV HBV Percent of Residual Risk due to Incidence donors, by Inventory Hold. Slide 20

21 I ll pause for a moment so you can let this information sink in. Slide 21

22 Viral Load in Manufacturing Pool Viral Load Detection limit (96 minipool) Residual Risk Chance of WP donation in pool Viral Load 1 WP/pool (6000 donations) Viral Load if ALL donations are WP HCV 675 IU/mL IU/mL 675 IU/mL HIV 4420 IU/mL IU/mL 4420 IU/mL HBV 220 IU/mL IU/mL 220 IU/mlL Slide 22

23 Effects on Viral Load Effect of Viral Inactivation / Removal on Viral Load Viral Load (IU/mL) 1 WP donation in pool All WP donations in pool 9 logs reduction 12 logs reduction 9 logs reduction 12 logs reduction HCV 1.1 / / / / HIV 7.4 / / / / 10 9 HBV 4.0 / / / / Assuming one WP donation in the manufacturing pool, viral load reduction is complete. Even assuming all donations are WP, an impossible scenario, viral inactivation/removal steps guarantee product safety. Slide 23

24 Inherent Truths Demographic variations in infectious disease prevalence and incidence exist. Viral removal and inactivation are key to ensuring the safety of fractionated plasma products. Risk of a potentially infectious unit entering the plasma manufacturing pool is small. Viral inactivation and removal significantly reduces the residual risk in finished plasma products. Slide 24

25 Differences exist in how patients, regulators and industry view the importance of donor quality compared to product quality but all stakeholders recognize the importance of product safety. Plasma derived products have never been safer as a result of the rigorous efforts of the industry to ensure quality donors, sensitive testing, and virus inactivation/removal technologies. Inherent Truths There has been no confirmed case of transmission of viral infection in more than two decades, attesting to the safety of plasma derived products. Slide 25

donors and collecting blood and plasma in for-profit or a not for profit environment

donors and collecting blood and plasma in for-profit or a not for profit environment Remunerated versus non-remunerated donors and collecting blood and plasma in for-profit or a not for profit environment ISBT Amsterdam, June 4, 2013 Jan M. Bult President PPTA PATIENT CENTEREDNESS IT

More information

IQPP Qualified Donor Standard

IQPP Qualified Donor Standard IQPP Qualified Donor Standard Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) IQPP Standards Program. PPTA's Voluntary Standards Program

More information

QSEAL Recovered Plasma Specification

QSEAL Recovered Plasma Specification QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards

More information

WHO Parvovirus B19 Genotype Panel

WHO Parvovirus B19 Genotype Panel WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)

More information

Impact of multi-dye multiplex technology on testing algorithm

Impact of multi-dye multiplex technology on testing algorithm Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT

More information

Plasma for fractionation: South African Plasma Requirements

Plasma for fractionation: South African Plasma Requirements Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal

More information

Zpracování lidské plazmy

Zpracování lidské plazmy Zpracování lidské plazmy a bezpečnost koncentrátů plazmových pa pote proteinů ů MUDr. Ivan Vonke, OKH, Nemocnice Č.Budějovice, a.s. Raw material blood Hormons Proteins More than 120 plasma proteins 70-80g/Liter

More information

Lookback studies to assess viral risks The French experience

Lookback studies to assess viral risks The French experience Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance

More information

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010 15 December 2011 EMA/CHMP/BWP/360642/2010 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately

More information

transfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of

transfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of Haemovigilance and the residual risk of transfusion-transmissible Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations

More information

Hepa%%s E Virus Is it a Concern?

Hepa%%s E Virus Is it a Concern? IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido

More information

Qualified Donor Standard. Implemented 1997 Revised Version 3.0

Qualified Donor Standard. Implemented 1997 Revised Version 3.0 Implemented 1997 Revised 2006 Version 3.0 IQPP Contents I. Background... 3 II. Definitions... 3 III. Standard... 3 IV. Inspection and Compliance Verification... 4 Appendix 1: Questions & Answers... 5 Page

More information

Pathogen Safety Monograph. Baxter BioSurgery Products [North America]

Pathogen Safety Monograph. Baxter BioSurgery Products [North America] Pathogen Safety Monograph Baxter BioSurgery Products [North America] In the production of plasma-derived therapeutics, patient safety is of paramount importance. Pathogen Safety Monograph for Baxter BioSurgery

More information

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company

More information

Pathogen Safety and BSE / variant CJD

Pathogen Safety and BSE / variant CJD Pathogen Safety and BSE / variant CJD Thomas R. Kreil, Global Pathogen Safety Parenteral Drug Industry Plasma Protein Industry Summit September 7, 2017; Beijing Pathogen Safety Those who cannot remember

More information

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and

More information

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 23 November 2016 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2016-N-1502,

More information

Objectives. Methods. Results. Economic

Objectives. Methods. Results. Economic Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Adapted from Membe SK, Coyle D, Husereau D, Cimon

More information

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of

More information

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,

More information

INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono

INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE Yuyun SM Soedarmono 1 BACKGROUND Indonesia has more than 240 million population and approximately 25,000 hemophilia A patients Hemophilia A patients

More information

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets

More information

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected: PURPOSE: MATERIALS: To outline a procedure for removing, recalling and/or correcting blood products that do not meet the requirements of the FDA, AABB, or the blood center. Recall/Market Withdrawal Form

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test

More information

Using Donor Human Milk in Extremely Premature Infants

Using Donor Human Milk in Extremely Premature Infants Using Donor Human Milk in Extremely Premature Infants Introduction Scott Eaker, Vice President of Quality and Regulatory Affairs Scott Elster, Chief Executive Officer David Rechtman, MD, Chief Medical

More information

Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil,

Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 236 BJID 2004; 8 (June) Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 1991-2001 Emil Kupek Department of Public Health, Federal University of Santa Catarina,

More information

BLOOD DONATION AFTER ACUPUNCTURE: A JUSTIFIED DEFERRAL?

BLOOD DONATION AFTER ACUPUNCTURE: A JUSTIFIED DEFERRAL? BLOOD DONATION AFTER ACUPUNCTURE: A JUSTIFIED DEFERRAL? What if your patients want to donate blood? Are you aware that patients undergoing Acupuncture treatment, according to international guidelines,

More information

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia

More information

ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES

ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES 101-112 United States Blood Donor Policy on Gay Men: Adopting an Italian Individual Risk Assessment Policy Melissa Kong* I. INTRODUCTION

More information

RISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE

RISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE Receiving an organ transplant carries many risks, including the risk of getting a disease from the June 2017 donor. This is true for every organ we transplant. BC Transplant makes every effort to minimize

More information

Changing eligibility criteria for MSM: The Canadian Perspective

Changing eligibility criteria for MSM: The Canadian Perspective Changing eligibility criteria for MSM: The Canadian Perspective Mindy Goldman MD Canadian Blood Services ASFA & WAA Joint Meeting, San Francisco April 4, 2014 Outline - Historical background - International

More information

Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared

Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared R. Thermann, W. K. Roth IPFA / PEI 18 th international workshop on Surveillance and screening of blood borne pathogens Budapest,

More information

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies 2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1

More information

Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion

Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion Josiane Pillonel, Rachid Djoudi, Florence Lot, Chistophe Martinaud, Claire Sauvage, Marie Jauffret-Roustide,

More information

Overview of Blood Transfusion System of Iran:

Overview of Blood Transfusion System of Iran: Report Article Overview of Blood Transfusion System of Iran: 2002-2011 AM Cheraghali High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and University

More information

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related

More information

[Submitted Electronically]

[Submitted Electronically] [Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious

More information

Viral Hepatitis. WHO Regional Office for Europe July 2013

Viral Hepatitis. WHO Regional Office for Europe July 2013 Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,

More information

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

More information

A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration

A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration Shirley Stagg, Samantha Fernando, Amy Shackell, Peter Roberts, Joan Dalton Bio Products Laboratory,

More information

FDA Reentry Guidance

FDA Reentry Guidance FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process

More information

Center for Biologics Evaluation and Research

Center for Biologics Evaluation and Research Center for Biologics Evaluation and Research Current Activities Future Directions Washington, DC January 25, 2010 Karen Midthun, MD Acting Director, CBER CBER Our Mission To ensure the safety, purity,

More information

Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB

Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB Plasma Fractionation Evolved from a medical service to a global manufacturing industry Involves sophisticated industrial process High

More information

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead: CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled

More information

Product Monograph. Key Scientific Information

Product Monograph. Key Scientific Information Product Monograph Key Scientific Information Ko ate -DVI (Double Viral Inactivation) Infusion of more than 2 billion IUs worldwide with no confirmed cases of viral transmission.* Talecris is a leader in

More information

Public Health, Infections and Transplantation

Public Health, Infections and Transplantation Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation

More information

HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME

HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES

More information

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757

More information

Duration: 12 months May to April

Duration: 12 months May to April SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you

More information

Structure and duties of Blood service

Structure and duties of Blood service NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,

More information

Transfusion-transmitted Cytomegalovirus

Transfusion-transmitted Cytomegalovirus Transfusion-transmitted Cytomegalovirus Can you confidently abandon CMV seronegative products in the modern era of pre-storage leukoreduction? Jeannie Callum, BA, MD, FRCPC Really? Are we still talking

More information

Department of Health and Human Services

Department of Health and Human Services Friday, August 24, 2007 Part III Department of Health and Human Services Food and Drug Administration 2 CFR Parts 606 and 60 Current Good Manufacturing Practice for Blood and Blood Components; Notification

More information

Research Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario

Research Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario e Scientific World Journal, Article ID 173939, 4 pages http://dx.doi.org/10.1155/2014/173939 Research Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario Tulika Chandra,

More information

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview IPFA Workshop Session 7: REGULATORY CONSIDERATIONS TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview Mary Lavithis, CSL Behring Australia Presented at: IPFA Asia

More information

Assays to Address Emerging Threats to Blood Safety

Assays to Address Emerging Threats to Blood Safety Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of

More information

Non-reproductive tissues and cells Recommending authority/ association

Non-reproductive tissues and cells Recommending authority/ association Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legally binding More stringent - recommended Not legally binding and not recommended Non-reproductive tissues and cells

More information

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens Vincini GA*, Cabuang LM, Land S, Best SJ NRL London, 12 January 2011 NRL EQAS for NAT HCV Genotyping

More information

The Alphabet Soup of Viral Hepatitis Testing

The Alphabet Soup of Viral Hepatitis Testing The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 5 PURPOSE To provide guidelines on the treatment and care of patients with Hepatitis. POLICY Hepatitis is an injury to hepatic cells and an inflammatory process in the liver. The major causes

More information

Guide to the preparation, use and quality assurance of blood components

Guide to the preparation, use and quality assurance of blood components Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.

More information

Armed Services Blood Program

Armed Services Blood Program Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009

More information

SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat

SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic

More information

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as

More information

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries

More information

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI) Annual SHOT Report 2016 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.3 which can be viewed in the main report. Case reports

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),

More information

APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION*

APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION* 11 APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION* Hisami IKEDA** Asian Med. J. 44(1): 11 21, 2000 Abstract: In the field of blood transfusion, risk management is defined

More information

EMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL PRODUCTS WITH PARTICULAR FOCUS ON NON-ENVELOPED VIRUSES. 13 September 2000 REPORT SUMMARY

EMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL PRODUCTS WITH PARTICULAR FOCUS ON NON-ENVELOPED VIRUSES. 13 September 2000 REPORT SUMMARY The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 28 March 2001 CPMP/BWP/BPWG/4080/00 EMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL

More information

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM

More information

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Verified with regard to factual content 13.12.2011 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER GAMMA anty-hbs 1000 Immunoglobulinum humanum hepatitidis B Human immunoglobulin against Hepatitis

More information

Juventas SHARING LIFE CONSENT FOR PLASMA INFUSION

Juventas SHARING LIFE CONSENT FOR PLASMA INFUSION Juventas SHARING LIFE Print Name Date of Birth CONSENT FOR PLASMA INFUSION To the Patient or Guardian of the Patient: The purpose of this document is to provide written information as of (month and day),

More information

Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening

Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram Timeline of introduction of microbiological tests

More information

Surveillance Report 2014

Surveillance Report 2014 Surveillance Report 2014 Executive summary We are pleased to present the third report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the

More information

Hepatitis C Cure The Invisible Epidemic

Hepatitis C Cure The Invisible Epidemic Hepatitis C Cure The Invisible Epidemic Iris House 8 Th Annual Face of AIDS Summit Hadiyah Charles Hepatitis Advocacy Manager Harm Reduction Coalition Hepatitis C Basics A virus that can cause chronic

More information

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING 28-29October2010 Issue Summary Informational Topic: FDA s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission

More information

WORLD HEALTH ORGANIZATION. Blood safety: proposal to establish World Blood Donor Day

WORLD HEALTH ORGANIZATION. Blood safety: proposal to establish World Blood Donor Day WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB115/9 115th Session 25 November 2004 Provisional agenda item 4.6 Blood safety: proposal to establish World Blood Donor Day Report by the Secretariat 1. Blood

More information

Table 2.1. Cohort Studies of HCV and Hepatocellular Carcinoma

Table 2.1. Cohort Studies of HCV and Hepatocellular Carcinoma Americas Guiltinan et al. (2008) USA Retrospective cohort of 10259 anti- HCV-positive allogeneic blood donors (6627 men, 3632 women) and 10259 anti-hcv-negative donors (6627 men, 3632 women) matched to

More information

DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA. Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1

DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA. Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1 DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1 OUTLINE Introduction Challenges to Fulfill Global Demand of Plasma for

More information

KNOWLEDGE INFUSION: FOCUS ON RISK-BASED DECISION-MAKING

KNOWLEDGE INFUSION: FOCUS ON RISK-BASED DECISION-MAKING KNOWLEDGE INFUSION: FOCUS ON RISK-BASED DECISION-MAKING Permission to Use: Please note that the presenter has agreed to make their presentation available. However, should you want to use some of the data

More information

Chapter 17: Transfusion-Transmitted Infections (TTI)

Chapter 17: Transfusion-Transmitted Infections (TTI) Annual SHOT Report 2014 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.2 which can be viewed in the main report. Case reports

More information

Hot Topics in Tissue Safety

Hot Topics in Tissue Safety Hot Topics in Tissue Safety 37 th Annual AATB Meeting National Harbor, Maryland 03 October 2013 Scott A. Brubaker, CTBS Chief Policy Officer PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis

More information

Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies

Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Case 1 FDA, Legal, and EBAA Medical Standards Panel Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Medical Directors Symposium Eye Bank Association of America Annual Meeting 47 y/o

More information

Informed Consent for Liver Transplant Patients

Informed Consent for Liver Transplant Patients Informed Consent for Liver Transplant Patients Evaluation Process You will be evaluated with consultations, lab tests and various procedures to determine the medical appropriateness of liver transplant.

More information

Situation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011

Situation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients

More information

PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291

PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291 PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291 Sexual risk behaviour and blood donation Part I: Blood donations by MSM This version was validated by the Board on October 2016 1 This advisory report

More information

Fact Sheet Blood Collection and Use Hong Kong Red Cross Blood Transfusion Service The Hong Kong Red Cross began its voluntary, nonremunerated blood donation programme to supply blood to all hospitals in

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI

More information

Keeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD

Keeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD Keeping the Blood Supply Safe Current and Future Strategies Marissa Li, MD Overview Pre-collection Donor Screening Collection Visual Inspection Aseptic Processing Leukoreduction of Apheresis Collections

More information

iphis Case ID #: Reported Date: Reporting Source: Diagnosing Health Unit: Branch Office: Outbreak Number:

iphis Case ID #: Reported Date: Reporting Source: Diagnosing Health Unit: Branch Office: Outbreak Number: Case Investigation Form: Hepatitis C Legend iphis system mandatory Required Case Information (add dates as YYYY-MM-DD) Case s Last Name: Case s First Name: Middle Name: Birth Date: Male Gender: Female

More information

Update on Transfusion- Transmitted Infectious Diseases

Update on Transfusion- Transmitted Infectious Diseases Update on Transfusion- Transmitted Infectious Diseases Scott Koepsell MD PhD Associate Professor University of Nebraska Medical Center I have no conflicts of interest to disclose. Global changes and the

More information

HEV Assay Development Update

HEV Assay Development Update HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening

More information

Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products

Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products WORLD HEALTH ORGANIZATION ORGANIZATION MONDIALE DE LA SANTE ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 26 to 30 November 2001 Guidelines on Viral Inactivation and Removal Procedures

More information

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK Federal, State and AABB requirements for nonconforming product investigation and recipient look back for adverse impact Stacy Ralston MPH, CLS (ASCP), RAC

More information

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38 2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally

More information

Exploring the risks of liver cancer after successful treatment for hepatitis C virus

Exploring the risks of liver cancer after successful treatment for hepatitis C virus CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,

More information

Patient Name: MRN: DOB: Treatment Location:

Patient Name: MRN: DOB: Treatment Location: Page 1 of 5 I. TO (Required) This Section is required to be completed by all patients who undergo kidney transplant surgery. I hereby consent to and authorize Dr. and his/her assistant(s), including supervised

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00) The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN

More information